2302 GMT - All eyes are now on the U.S. Food and Drug Administration as it weighs clearance of Echo IQ's EchoSolv heart-failure product, says Petra Capital. Clearance will trigger another A$10 million payment as part of Echo IQ's heads of agreement with Pro Medicus, which establishes a U.S. commercial partnership. Analyst Tanushree Jain says FDA clearance is highly likely and key to unlocking the U.S. commercial opportunity. She says that, timing wise, it has parallels to Pro Medicus's investment in ASX-listed 4DMedical. This investment was made just before FDA clearance of 4DMedical's CTVQ product and led to 4DMedical's share price rising strongly, which continued after FDA clearance. Petra Capital lifts its price target on Echo IQ by 19%, to A$1.30/share, and retains a "hold" call. Echo IQ ended Thursday at A$1.615. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

June 25, 2026 19:02 ET (23:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.